Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Six Years Later: FDA’s New Enforcement Paradigm

This article was originally published in RPM Report

Executive Summary

FDA’s top compliance official, Howard Sklamberg, used his annual update to the Food & Drug Law Institute to reflect on the changes in FDA’s enforcement structure and authorities during the tenure of Margaret Hamburg, who stepped down after six years as Commissioner of FDA in April.

You may also be interested in...



Policy People In The News: Neomi Rao Confirmed To Head White House Reg Office

Former US FDA global regulator Howard Sklamberg joins law firm Akin Gump; PhRMA adds two VPS; more changes in personnel.

Top US FDA Global Regulator Joins Major Law Firm's Health-Care Division

Howard Sklamberg, the former US FDA deputy commissioner for global regulatory operations and policy who left the agency in April, will now join the health-care practice at the law firm Akin Gump.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS079854

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel